Optimizing immunosuppression after heart transplant
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether combining everolimus with a lower dose of a standard anti-rejection drug (calcineurin inhibitor) can help heart transplant patients in Korea have fewer side effects while keeping their new heart healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You are between 28 and 100 days after your heart transplant.
- Your doctor thinks you are suitable for a combination of everolimus and a calcineurin inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether using heart-monitoring blood tests and biopsy results can help customize (optimize) immune-suppression medication soon after your transplant. It aims to keep the transplanted heart safe while avoiding over- or under-treatment.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.